{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:00:51Z","timestamp":1792980051383,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["CIVICS Option 22B"],"award-info":[{"award-number":["CIVICS Option 22B"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01317-4","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:06:31Z","timestamp":1766747191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An influenza HA mRNA-LNP vaccine induces potent responses in newborn nonhuman primates that enhance protection from challenge"],"prefix":"10.1038","volume":"11","author":[{"given":"Courtney L.","family":"Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth C.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kali F.","family":"Crofts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad-Gabriel","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Caudell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha A.","family":"Alexander-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"1317_CR1","doi-asserted-by":"publisher","first-page":"29256","DOI":"10.3402\/ijch.v74.29256","volume":"74","author":"EM Foote","year":"2015","unstructured":"Foote, E. M. et al. Lower respiratory tract infection hospitalizations among American Indian\/Alaska Native children and the general United States child population. Int. J. Circumpolar Health 74, 29256 (2015).","journal-title":"Int. J. Circumpolar Health"},{"key":"1317_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/QCO.0b013e32832a58e4","volume":"22","author":"S Esposito","year":"2009","unstructured":"Esposito, S. & Principi, N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr. Opin. Infect. Dis. 22, 244\u2013249 (2009).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"1317_CR3","doi-asserted-by":"publisher","unstructured":"Shang, M., Blanton, L., Brammer, L., Olsen, S. J. & Fry, A. M. Influenza-associated pediatric deaths in the United States, 2010\u20132016. Pediatrics 141, https:\/\/doi.org\/10.1542\/peds.2017-2918 (2018).","DOI":"10.1542\/peds.2017-2918"},{"key":"1317_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.15585\/mmwr.mm7346a1","volume":"73","author":"JL Kriss","year":"2024","unstructured":"Kriss, J. L. et al. Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2024. MMWR Morb. Mortal. Wkly. Rep. 73, 1044\u20131051 (2024).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"1317_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1542\/peds.87.6.823","volume":"87","author":"JR Groothuis","year":"1991","unstructured":"Groothuis, J. R., Levin, M. J., Rabalais, G. P., Meiklejohn, G. & Lauer, B. A. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics 87, 823\u2013828 (1991).","journal-title":"Pediatrics"},{"key":"1317_CR6","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1086\/587643","volume":"197","author":"NB Halasa","year":"2008","unstructured":"Halasa, N. B., Gerber, M. A., Chen, Q., Wright, P. F. & Edwards, K. M. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J. Infect. Dis. 197, 1448\u20131454 (2008).","journal-title":"J. Infect. Dis."},{"key":"1317_CR7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/INF.0b013e3181b0c0ca","volume":"28","author":"EB Walter","year":"2009","unstructured":"Walter, E. B. et al. Trivalent inactivated influenza virus vaccine given to two-month-old children. Pediatr. Infect. Dis. J. 28, 1099\u20131104 (2009).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1317_CR8","first-page":"105","volume":"29","author":"JA Englund","year":"2010","unstructured":"Englund, J. A. et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Randomized Controlled Trial. 29, 105\u2013110 (2010).","journal-title":"Randomized Controlled Trial."},{"key":"1317_CR9","doi-asserted-by":"publisher","unstructured":"Quincer, E. M., Cranmer, L. M. & Kamidani, S. Prenatal maternal immunization for infant protection: a review of the vaccines recommended, infant immunity and future research directions. Pathogens 13, https:\/\/doi.org\/10.3390\/pathogens13030200(2024).","DOI":"10.3390\/pathogens13030200"},{"key":"1317_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fimmu.2020.00555","volume":"11","author":"M Albrecht","year":"2020","unstructured":"Albrecht, M. & Arck, P. C. Vertically transferred immunity in neonates: mothers, mechanisms and mediators. Front. Immunol. 11, 555\u2013555 (2020).","journal-title":"Front. Immunol."},{"key":"1317_CR11","doi-asserted-by":"publisher","unstructured":"Willis, E. et al. Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. Sci. Transl. Med. 12, https:\/\/doi.org\/10.1126\/scitranslmed.aav5701 (2020).","DOI":"10.1126\/scitranslmed.aav5701"},{"key":"1317_CR12","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1016\/j.vaccine.2020.05.059","volume":"38","author":"FM Munoz","year":"2020","unstructured":"Munoz, F. M. et al. Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. Vaccine 38, 5355\u20135363 (2020).","journal-title":"Vaccine"},{"key":"1317_CR13","doi-asserted-by":"publisher","unstructured":"Crofts, K. F. & Alexander-Miller, M. A. Challenges for the newborn immune response to respiratory virus infection and vaccination. Vaccines (Basel) 8, https:\/\/doi.org\/10.3390\/vaccines8040558 (2020).","DOI":"10.3390\/vaccines8040558"},{"key":"1317_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568651","volume":"11","author":"MA Alexander-Miller","year":"2020","unstructured":"Alexander-Miller, M. A. Challenges for the newborn following influenza virus infection and prospects for an effective vaccine. Front. Immunol. 11, 568651 (2020).","journal-title":"Front. Immunol."},{"key":"1317_CR15","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jcpa.2007.04.004","volume":"137","author":"CA Siegrist","year":"2007","unstructured":"Siegrist, C. A. The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol. 137, S4\u20139 (2007).","journal-title":"J. Comp. Pathol."},{"key":"1317_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nri1394","volume":"4","author":"B Adkins","year":"2004","unstructured":"Adkins, B., Leclerc, C. & Marshall-Clarke, S. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4, 553\u2013564 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"1317_CR17","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.4049\/jimmunol.1203288","volume":"191","author":"I Debock","year":"2013","unstructured":"Debock, I. et al. Neonatal follicular Th cell responses are impaired and modulated by IL-4. J. Immunol. 191, 1231\u20131239 (2013).","journal-title":"J. Immunol."},{"key":"1317_CR18","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.4049\/jimmunol.1201143","volume":"189","author":"B Mastelic","year":"2012","unstructured":"Mastelic, B. et al. Environmental and T cell-intrinsic factors limit the expansion of neonatal follicular T helper cells but may be circumvented by specific adjuvants. J. Immunol. 189, 5764\u20135772 (2012).","journal-title":"J. Immunol."},{"key":"1317_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fimmu.2014.00085","volume":"5","author":"H Xu","year":"2014","unstructured":"Xu, H., Wang, X., Lackner, A. A. & Veazey, R. S. PD-1HIGH follicular CD4 T helper cell subsets residing in lymph node germinal centers correlate with B cell maturation and IgG production in rhesus macaques. Front. Immunol. 5, 85 (2014).","journal-title":"Front. Immunol."},{"key":"1317_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12396","volume":"270","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y., Garcia-Ibanez, L. & Toellner, K. M. Regulation of germinal center B-cell differentiation. Immunol. Rev. 270, 8\u201319 (2016).","journal-title":"Immunol. Rev."},{"key":"1317_CR21","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3389\/fimmu.2018.02469","volume":"9","author":"M Stebegg","year":"2018","unstructured":"Stebegg, M. et al. Regulation of the germinal center response. Front. Immunol. 9, 2469 (2018).","journal-title":"Front. Immunol."},{"key":"1317_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103656","volume":"25","author":"H Law","year":"2022","unstructured":"Law, H. et al. Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response. iScience 25, 103656 (2022).","journal-title":"iScience"},{"key":"1317_CR23","doi-asserted-by":"publisher","unstructured":"Linterman, M. A. & Hill, D. L. Can follicular helper T cells be targeted to improve vaccine efficacy? F1000Res 5, https:\/\/doi.org\/10.12688\/f1000research.7388.1 (2016).","DOI":"10.12688\/f1000research.7388.1"},{"key":"1317_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2015.02.007","volume":"34","author":"NS Butler","year":"2015","unstructured":"Butler, N. S. & Kulu, D. I. The regulation of T follicular helper responses during infection. Curr. Opin. Immunol. 34, 68\u201374 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"1317_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nri2508","volume":"9","author":"CA Siegrist","year":"2009","unstructured":"Siegrist, C. A. & Aspinall, R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9, 185\u2013194 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1317_CR26","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1182\/blood-2007-01-069245","volume":"110","author":"K Kaur","year":"2007","unstructured":"Kaur, K., Chowdhury, S., Greenspan, N. S. & Schreiber, J. R. Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates. Blood 110, 2948\u20132954 (2007).","journal-title":"Blood"},{"key":"1317_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","volume":"24","author":"FB Vincent","year":"2013","unstructured":"Vincent, F. B., Saulep-Easton, D., Figgett, W. A., Fairfax, K. A. & Mackay, F. The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24, 203\u2013215 (2013).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1317_CR28","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2007-09-110858","volume":"111","author":"E Belnoue","year":"2008","unstructured":"Belnoue, E. et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111, 2755\u20132764 (2008).","journal-title":"Blood"},{"key":"1317_CR29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6 mRNA-based therapeutics\u2212developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1317_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39376-7","volume":"14","author":"IT Lee","year":"2023","unstructured":"Lee, I. T. et al. Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).","journal-title":"Nat. Commun."},{"key":"1317_CR31","doi-asserted-by":"publisher","unstructured":"Subbarao, S. et al. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer\/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Euro Surveill. 26, https:\/\/doi.org\/10.2807\/1560-7917.Es.2021.26.12.2100329 (2021).","DOI":"10.2807\/1560-7917.Es.2021.26.12.2100329"},{"key":"1317_CR32","doi-asserted-by":"publisher","unstructured":"Garrido, C. et al. SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Science immunology 6, https:\/\/doi.org\/10.1126\/sciimmunol.abj3684 (2021).","DOI":"10.1126\/sciimmunol.abj3684"},{"key":"1317_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2209367","volume":"387","author":"EJ Anderson","year":"2022","unstructured":"Anderson, E. J. et al. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. N. Engl. J. Med. 387, 1673\u20131687 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1317_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/vaccines12040415","volume":"12","author":"BC Holbrook","year":"2024","unstructured":"Holbrook, B. C., Clemens, E. A. & Alexander-Miller, M. A. Sex-dependent effects on influenza-specific antibody quantity and neutralizing activity following vaccination of newborn non-human primates is determined by adjuvants. Vaccines 12, 415 (2024).","journal-title":"Vaccines"},{"key":"1317_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00523-8","volume":"7","author":"EA Clemens","year":"2022","unstructured":"Clemens, E. A. et al. TLR agonists induce sustained IgG to hemagglutinin stem and modulate T cells following newborn vaccination. NPJ Vaccines 7, 102 (2022).","journal-title":"NPJ Vaccines"},{"key":"1317_CR36","doi-asserted-by":"publisher","first-page":"135449","DOI":"10.1172\/jci.insight.135449","volume":"5","author":"E Clemens","year":"2020","unstructured":"Clemens, E. et al. Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem. JCI Insight 5, 135449 (2020). pii.","journal-title":"JCI Insight"},{"key":"1317_CR37","doi-asserted-by":"publisher","unstructured":"Clemens, E. A. et al. An R848 conjugated influenza virus vaccine elicits robust IgG to hemagglutinin stem in a newborn nonhuman primate model. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiaa728 (2020).","DOI":"10.1093\/infdis\/jiaa728"},{"key":"1317_CR38","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/imm.12845","volume":"153","author":"BC Holbrook","year":"2018","unstructured":"Holbrook, B. C. et al. An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates. Immunology 153, 357\u2013367 (2018).","journal-title":"Immunology"},{"key":"1317_CR39","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1016\/j.vaccine.2017.09.054","volume":"35","author":"BC Holbrook","year":"2017","unstructured":"Holbrook, B. C. et al. Adjuvanting an inactivated influenza vaccine with conjugated R848 improves the level of antibody present at 6 months in a nonhuman primate neonate model. Vaccine 35, 6137\u20136142 (2017).","journal-title":"Vaccine"},{"key":"1317_CR40","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1016\/j.vaccine.2016.08.010","volume":"34","author":"BC Holbrook","year":"2016","unstructured":"Holbrook, B. C., D\u2019Agostino, R. B. Jr., Parks, G. D. & Alexander-Miller, M. A. Adjuvanting an inactivated influenza vaccine with flagellin improves the function and quantity of the long-term antibody response in a nonhuman primate neonate model. Vaccine 34, 4712\u20134717 (2016).","journal-title":"Vaccine"},{"key":"1317_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4049\/jimmunol.1600497","volume":"197","author":"BC Holbrook","year":"2016","unstructured":"Holbrook, B. C. et al. A novel R848-conjugated inactivated influenza virus vaccine is efficacious and safe in a neonate nonhuman primate model. J. Immunol. 197, 555\u2013564 (2016).","journal-title":"J. Immunol."},{"key":"1317_CR42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.virol.2014.12.007","volume":"476","author":"BC Holbrook","year":"2015","unstructured":"Holbrook, B. C. et al. Nonhuman primate infants have an impaired respiratory but not systemic IgG antibody response following influenza virus infection. Virology 476, 124\u2013133 (2015).","journal-title":"Virology"},{"key":"1317_CR43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-animal-021419-083813","volume":"10","author":"AF Tarantal","year":"2022","unstructured":"Tarantal, A. F., Noctor, S. C. & Hartigan-O\u2019Connor, D. J. Nonhuman primates in translational research. Annu. Rev. Anim. Biosci. 10, 441\u2013468 (2022).","journal-title":"Annu. Rev. Anim. Biosci."},{"key":"1317_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.exger.2016.12.005","volume":"94","author":"JA Mattison","year":"2017","unstructured":"Mattison, J. A. & Vaughan, K. L. An overview of nonhuman primates in aging research. Exp. Gerontol. 94, 41\u201345 (2017).","journal-title":"Exp. Gerontol."},{"key":"1317_CR45","doi-asserted-by":"publisher","first-page":"8139","DOI":"10.1128\/JVI.00425-14","volume":"88","author":"Y Matsuoka","year":"2014","unstructured":"Matsuoka, Y. et al. African Green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine Candidates. J. Virol. 88, 8139\u20138152 (2014).","journal-title":"J. Virol."},{"key":"1317_CR46","doi-asserted-by":"publisher","unstructured":"Federico, M. The immunologic downsides associated with the powerful translation of current COVID-19 vaccine mRNA can be overcome by mucosal vaccines. Vaccines (Basel) 12, https:\/\/doi.org\/10.3390\/vaccines12111281 (2024).","DOI":"10.3390\/vaccines12111281"},{"key":"1317_CR47","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-med-120617-041310","volume":"71","author":"R Nachbagauer","year":"2020","unstructured":"Nachbagauer, R. & Palese, P. Is a universal influenza virus vaccine possible?Annu. Rev. Med. 71, 315\u2013327 (2020).","journal-title":"Annu. Rev. Med."},{"key":"1317_CR48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1172\/JCI123366","volume":"129","author":"HX Tan","year":"2019","unstructured":"Tan, H. X. et al. Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem. J. Clin. Invest. 129, 850\u2013862 (2019).","journal-title":"J. Clin. Invest."},{"key":"1317_CR49","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1089\/vim.2017.0129","volume":"31","author":"MO Altman","year":"2018","unstructured":"Altman, M. O., Angeletti, D. & Yewdell, J. W. Antibody immunodominance: the key to understanding influenza virus antigenic drift. Viral Immunol. 31, 142\u2013149 (2018).","journal-title":"Viral Immunol."},{"key":"1317_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 9, 3361 (2018).","journal-title":"Nat. Commun."},{"key":"1317_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26538-7","volume":"8","author":"HM Yassine","year":"2018","unstructured":"Yassine, H. M. et al. Use of hemagglutinin stem probes demonstrate prevalence of broadly reactive Group 1 influenza antibodies in human sera. Sci. Rep. 8, 8628 (2018).","journal-title":"Sci. Rep."},{"key":"1317_CR52","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","volume":"333","author":"D Corti","year":"2011","unstructured":"Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850\u2013856 (2011).","journal-title":"Science"},{"key":"1317_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imr.12861","volume":"296","author":"RK Abbott","year":"2020","unstructured":"Abbott, R. K. & Crotty, S. Factors in B cell competition and immunodominance. Immunol. Rev. 296, 120\u2013131 (2020).","journal-title":"Immunol. Rev."},{"key":"1317_CR54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","volume":"604","author":"W Kim","year":"2022","unstructured":"Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141\u2013145 (2022).","journal-title":"Nature"},{"key":"1317_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2022.152279","volume":"227","author":"PM Varghese","year":"2022","unstructured":"Varghese, P. M., Kishore, U. & Rajkumari, R. Innate and adaptive immune responses against Influenza A Virus: Immune evasion and vaccination strategies. Immunobiology 227, 152279. https:\/\/doi.org\/10.1016\/j.imbio.2022.152279 (2022).","journal-title":"Immunobiology"},{"key":"1317_CR56","doi-asserted-by":"publisher","first-page":"e1009724","DOI":"10.1371\/journal.ppat.1009724","volume":"17","author":"YA Ko","year":"2021","unstructured":"Ko, Y. A. et al. A non-neutralizing antibody broadly protects against influenza virus infection by engaging effector cells. PLoS Pathog. 17, e1009724 (2021).","journal-title":"PLoS Pathog."},{"key":"1317_CR57","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1080\/21645515.2021.1976580","volume":"17","author":"BM Gunn","year":"2021","unstructured":"Gunn, B. M. & Bai, S. Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. Hum. Vaccin. Immunother. 17, 4328\u20134344 (2021).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1317_CR58","doi-asserted-by":"publisher","unstructured":"Zhang, Y. et al. Targeting hemagglutinin: approaches for broad protection against the influenza A virus. Viruses 11, https:\/\/doi.org\/10.3390\/v11050405 (2019).","DOI":"10.3390\/v11050405"},{"key":"1317_CR59","doi-asserted-by":"publisher","unstructured":"Motsoeneng, B. M. et al. Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza-illness after seasonal influenza vaccination in pregnant women. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiae241 (2024).","DOI":"10.1093\/infdis\/jiae241"},{"key":"1317_CR60","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1317_CR61","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1128\/JVI.03422-13","volume":"88","author":"JRR Whittle","year":"2014","unstructured":"Whittle, J. R. R. et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J. Virol. 88, 4047\u20134057 (2014).","journal-title":"J. Virol."},{"key":"1317_CR62","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jim.2012.09.014","volume":"387","author":"L Nettenstrom","year":"2013","unstructured":"Nettenstrom, L. et al. An optimized multi-parameter flow cytometry protocol for human T regulatory cell analysis on fresh and viably frozen cells, correlation with epigenetic analysis, and comparison of cord and adult blood. J. Immunol. Methods 387, 81\u201388 (2013).","journal-title":"J. Immunol. Methods"},{"key":"1317_CR63","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/eji.200939638","volume":"40","author":"KL Flanagan","year":"2010","unstructured":"Flanagan, K. L. et al. The effect of placental malaria infection on cord blood and maternal immunoregulatory responses at birth. Eur. J. Immunol. 40, 1062\u20131072 (2010).","journal-title":"Eur. J. Immunol."},{"key":"1317_CR64","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.4049\/jimmunol.2000461","volume":"205","author":"BC Holbrook","year":"2020","unstructured":"Holbrook, B. C. & Alexander-Miller, M. A. Higher frequency and increased expression of molecules associated with suppression on T regulatory cells from newborn compared with adult nonhuman primates. J. Immunol. 205, 2128\u20132136 (2020).","journal-title":"J. Immunol."},{"key":"1317_CR65","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.3389\/fimmu.2018.03049","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang, J. et al. IL-6 impairs vaccine responses in neonatal mice. Front. Immunol. 9, 3049 (2018).","journal-title":"Front. Immunol."},{"key":"1317_CR66","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s13075-014-0471-7","volume":"16","author":"I Vanderleyden","year":"2014","unstructured":"Vanderleyden, I., Linterman, M. A. & Smith, K. G. Regulatory T cells and control of the germinal centre response. Arthritis Res. Ther. 16, 471 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"1317_CR67","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1172\/JCI76861","volume":"124","author":"PT Sage","year":"2014","unstructured":"Sage, P. T., Alvarez, D., Godec, J., von Andrian, U. H. & Sharpe, A. H. Circulating T follicular regulatory and helper cells have memory-like properties. J. Clin. Invest. 124, 5191\u20135204 (2014).","journal-title":"J. Clin. Invest."},{"key":"1317_CR68","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/ni.3578","volume":"17","author":"PT Sage","year":"2016","unstructured":"Sage, P. T. et al. Suppression by TFR cells leads to durable and selective inhibition of B cell effector function. Nat. Immunol. 17, 1436\u20131446 (2016).","journal-title":"Nat. Immunol."},{"key":"1317_CR69","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.4049\/jimmunol.1302503","volume":"193","author":"RS Herati","year":"2014","unstructured":"Herati, R. S. et al. Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J. Immunol. 193, 3528\u20133537 (2014).","journal-title":"J. Immunol."},{"key":"1317_CR70","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.celrep.2015.09.004","volume":"13","author":"N Obeng-Adjei","year":"2015","unstructured":"Obeng-Adjei, N. et al. Circulating Th1-Cell-type Tfh Cells that exhibit impaired B cell help are preferentially activated during acute malaria in children. Cell Rep. 13, 425\u2013439 (2015).","journal-title":"Cell Rep."},{"key":"1317_CR71","doi-asserted-by":"publisher","first-page":"495848","DOI":"10.1155\/2013\/495848","volume":"2013","author":"A Chiaretti","year":"2013","unstructured":"Chiaretti, A. et al. IL-1 \u03b2 and IL-6 upregulation in children with H1N1 influenza virus infection. Mediators Inflamm. 2013, 495848 (2013).","journal-title":"Mediators Inflamm."},{"key":"1317_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00901-4","volume":"9","author":"RN England","year":"2024","unstructured":"England, R. N. et al. Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model. NPJ Vaccines 9, 110 (2024).","journal-title":"NPJ Vaccines"},{"key":"1317_CR73","doi-asserted-by":"publisher","first-page":"eadd6383","DOI":"10.1126\/scitranslmed.add6383","volume":"15","author":"EC Milligan","year":"2023","unstructured":"Milligan, E. C. et al. Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later. Sci. Transl. Med. 15, eadd6383 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1317_CR74","doi-asserted-by":"publisher","unstructured":"Chen, T. et al. Protective immune responses induced by an mRNA-LNP vaccine encoding prm-e proteins against japanese encephalitis virus infection. Viruses 14, https:\/\/doi.org\/10.3390\/v14061121 (2022).","DOI":"10.3390\/v14061121"},{"key":"1317_CR75","unstructured":"United States, F. & Drug, A. Vaccines and Related Biological Products Advisory Committee Meeting: FDA Briefing Document, Novavax COVID-19 Vaccine (U.S. Department of Health and Human Services, Food and Drug Administration, 2022)."},{"key":"1317_CR76","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.immuni.2017.03.009","volume":"46","author":"TR Kollmann","year":"2017","unstructured":"Kollmann, T. R., Kampmann, B., Mazmanian, S. K., Marchant, A. & Levy, O. Protecting the newborn and young infant from infectious diseases: Lessons from immune ontogeny. Immunity 46, 350\u2013363 (2017).","journal-title":"Immunity"},{"key":"1317_CR77","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41577-018-0005-7","volume":"18","author":"JD Estes","year":"2018","unstructured":"Estes, J. D., Wong, S. W. & Brenchley, J. M. Nonhuman primate models of human viral infections. Nat. Rev. Immunol. 18, 390\u2013404 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1317_CR78","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ilar\/ilx030","volume":"58","author":"LA Miller","year":"2017","unstructured":"Miller, L. A., Royer, C. M., Pinkerton, K. E. & Schelegle, E. S. Nonhuman primate models of respiratory disease: past, present, and future. ILAR j. 58, 269\u2013280 (2017).","journal-title":"ILAR j."},{"key":"1317_CR79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2015.02.011","volume":"117","author":"AS Davis","year":"2015","unstructured":"Davis, A. S., Taubenberger, J. K. & Bray, M. The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014. Antivir. Res. 117, 75\u201398 (2015).","journal-title":"Antivir. Res."},{"key":"1317_CR80","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/ilar\/ilt049","volume":"54","author":"AJ Jasinska","year":"2013","unstructured":"Jasinska, A. J. et al. Systems biology of the vervet monkey. ILAR J. 54, 122\u2013143 (2013).","journal-title":"ILAR J."},{"key":"1317_CR81","first-page":"140","volume":"10","author":"N Makori","year":"2003","unstructured":"Makori, N. et al. Functional and morphological development of lymphoid tissues and immune regulatory and effector function in rhesus monkeys: cytokine-secreting cells, immunoglobulin-secreting cells, and CD5(+) B-1 cells appear early in fetal development. Clin. Diagn. Lab Immunol. 10, 140\u2013153 (2003).","journal-title":"Clin. Diagn. Lab Immunol."},{"key":"1317_CR82","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/bdrb.10035","volume":"68","author":"MP Holsapple","year":"2003","unstructured":"Holsapple, M. P., West, L. J. & Landreth, K. S. Species comparison of anatomical and functional immune system development. Birth Defects Res. B: Dev. Reprod. Toxicol. 68, 321\u2013334 (2003).","journal-title":"Birth Defects Res. B: Dev. Reprod. Toxicol."},{"key":"1317_CR83","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03036-23","volume":"15","author":"KA Bowman","year":"2024","unstructured":"Bowman, K. A., Kaplonek, P. & McNamara, R. P. Understanding Fc function for rational vaccine design against pathogens. mBio 15, e0303623. https:\/\/doi.org\/10.1128\/mbio.03036-23 (2024).","journal-title":"mBio"},{"key":"1317_CR84","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang, A. et al. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat. Rev. Immunol. 23, 381\u2013396 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1317_CR85","doi-asserted-by":"publisher","unstructured":"Semmes, E. C. et al. Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection. J. Clin. Invest. 132, https:\/\/doi.org\/10.1172\/jci156827 (2022).","DOI":"10.1172\/jci156827"},{"key":"1317_CR86","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3389\/fimmu.2014.00393","volume":"5","author":"I Debock","year":"2014","unstructured":"Debock, I. & Flamand, V. Unbalanced neonatal CD4+ T-cell immunity. Front. Immunol. 5, 393 (2014).","journal-title":"Front. Immunol."},{"key":"1317_CR87","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3389\/fmicb.2014.00477","volume":"5","author":"J Ndure","year":"2014","unstructured":"Ndure, J. & Flanagan, K. L. Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front. Microbiol. 5, 477 (2014).","journal-title":"Front. Microbiol."},{"key":"1317_CR88","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.0105-2896.2006.00412.x","volume":"212","author":"BT Rouse","year":"2006","unstructured":"Rouse, B. T., Sarangi, P. P. & Suvas, S. Regulatory T cells in virus infections. Immunol. Rev. 212, 272\u2013286 (2006).","journal-title":"Immunol. Rev."},{"key":"1317_CR89","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","volume":"21","author":"S Sakaguchi","year":"2009","unstructured":"Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P. & Yamaguchi, T. Regulatory T cells: how do they suppress immune responses?. Int. Immunol. 21, 1105\u20131111 (2009).","journal-title":"Int. Immunol."},{"key":"1317_CR90","doi-asserted-by":"publisher","unstructured":"Lin, P.-H. et al. Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection. Mucosal Immunol. https:\/\/doi.org\/10.1038\/s41385-018-0004-9 (2018).","DOI":"10.1038\/s41385-018-0004-9"},{"key":"1317_CR91","doi-asserted-by":"publisher","first-page":"595297","DOI":"10.3389\/fimmu.2020.595297","volume":"11","author":"EC Semmes","year":"2020","unstructured":"Semmes, E. C. et al. Understanding early-life adaptive immunity to guide interventions for pediatric health. Front. Immunol. 11, 595297 (2020).","journal-title":"Front. Immunol."},{"key":"1317_CR92","doi-asserted-by":"publisher","unstructured":"McIntire, K. M. et al. Maturation of germinal center B cells after influenza virus vaccination in humans. J. Exp. Med. 221, https:\/\/doi.org\/10.1084\/jem.20240668 (2024).","DOI":"10.1084\/jem.20240668"},{"key":"1317_CR93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-62703-260-5_2","volume":"969","author":"N Pardi","year":"2013","unstructured":"Pardi, N., Muramatsu, H., Weissman, D. & Kariko, K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol. 969, 29\u201342 (2013).","journal-title":"Methods Mol. Biol."},{"key":"1317_CR94","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1126\/science.1178258","volume":"326","author":"SE Hensley","year":"2009","unstructured":"Hensley, S. E. et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326, 734\u2013736 (2009).","journal-title":"Science"},{"key":"1317_CR95","doi-asserted-by":"publisher","first-page":"12039","DOI":"10.1128\/JVI.01650-12","volume":"86","author":"MD Alpert","year":"2012","unstructured":"Alpert, M. D. et al. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J. Virol. 86, 12039\u201312052 (2012).","journal-title":"J. Virol."},{"key":"1317_CR96","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.vaccine.2016.11.082","volume":"35","author":"RD de Vries","year":"2017","unstructured":"de Vries, R. D. et al. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. Vaccine 35, 238\u2013247 (2017).","journal-title":"Vaccine"},{"key":"1317_CR97","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","volume":"366","author":"ME Ackerman","year":"2011","unstructured":"Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8\u201319 (2011).","journal-title":"J. Immunol. Methods"},{"key":"1317_CR98","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1172\/JCI129520","volume":"130","author":"CM Boudreau","year":"2020","unstructured":"Boudreau, C. M. et al. Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination. J. Clin. Invest. 130, 662\u2013672 (2020).","journal-title":"J. Clin. Invest."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01317-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T18:01:58Z","timestamp":1768672918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01317-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01317-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Dr. Drew Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. The authors have no additional financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}